Pharmaceutical Technology
DECEMBER 3, 2024
Many machines are required for pharmaceutical milling processes. Can you reduce that number, streamline operations and improve efficiency?
Bio Pharma Dive
DECEMBER 3, 2024
While early and from a small trial, the findings suggest Janux’s method of “masking” T cell engagers could lead to differentiated results, some analysts said.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
DECEMBER 3, 2024
Olema Oncology and Novartis have signed a clinical trial collaboration and supply agreement for a Phase III trial in metastatic breast cancer.
Bio Pharma Dive
DECEMBER 3, 2024
The company reached a deal to divest its third biosimilar this year, selling a copycat version of Amgen’s Neulasta for up to $558 million.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Rethinking Clinical Trials
DECEMBER 3, 2024
In a new report from the NIH Pragmatic Trials Collaboratory, a team of bioethicists explores the ethical obligation to share aggregate results from pragmatic clinical trials with research participants. They conclude with recommendations for how to meet this obligation. The article was published online ahead of print in Clinical Trials. There is growing appreciation of the importance of sharing aggregate results of clinical trials with research participants.
Pharmaceutical Technology
DECEMBER 3, 2024
Turkiye’s pharmaceutical industry has grappled with significant economic challenges such as the frequent upward revision of the pharmaceutical Euro exchange rate.
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
DECEMBER 3, 2024
Drugs such as Cobenfy could reshape the antipsychotic market, providing a more nuanced range of patient options.
Bio Pharma Dive
DECEMBER 3, 2024
A change in ownership and what it means for our readers.
Pharmaceutical Technology
DECEMBER 3, 2024
Lundbeck has completed the acquisition of all outstanding shares of Longboard Pharmaceuticals, to bolster the neuro-rare disease sector.
Fierce Pharma
DECEMBER 3, 2024
Over the last two-plus years, as Eli Lilly and Novo Nordisk have battled for their share of the massive weight loss market and patients wondered which company’s products were more effective, there | Eli Lilly revealed results from a study that showed its obesity drug Zepbound was 47% more effective than Novo’s Wegovy in helping patients lose weight.
Pharmaceutical Technology
DECEMBER 3, 2024
J&J is seeking approval of TREMFYA for paediatric conditions with the submission of two sBLA to the US Food and Drug Administration.
pharmaphorum
DECEMBER 3, 2024
The MHRA has reminded pharma companies that from 1st January all medicines sold in the UK will have to comply with new labelling requirements
Pharmaceutical Technology
DECEMBER 3, 2024
Novartis has entered a worldwide licence and partnership agreement with PTC Therapeutics for the development of PTC518.
Pharma Times
DECEMBER 3, 2024
Partnership aims to develop new radiopharmaceuticals for cancer treatment
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Drug Patent Watch
DECEMBER 3, 2024
In the ever-evolving landscape of pharmaceutical research and development, a revolutionary force is reshaping the way we approach drug discovery and repurposing. This force is none other than Artificial Intelligence (AI) and Machine Learning (ML).
Pharma Times
DECEMBER 3, 2024
Immunocore has announced that Kimmtrak (tebentafusp) has been recommended for funding in England by the National Institute for Health and Care Excellence (NICE) and is now available through the NHS.
pharmaphorum
DECEMBER 3, 2024
Patients in England with a rare form of eye cancer will be able to access Kimmtrak, a TCR therapy from Immunocore, after NICE changes its position
XTalks
DECEMBER 3, 2024
Novocure, a global leader in oncology innovation, has long been at the forefront of advancing tumor treating fields (TTFields) therapy. This technology, already approved by the US Food and Drug Administration (FDA) for glioblastoma and mesothelioma , and most recently for metastatic non-small cell lung cancer (NSCLC), harnesses electric fields to disrupt cancer cell division.
pharmaphorum
DECEMBER 3, 2024
Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415m.
Outsourcing Pharma
DECEMBER 3, 2024
Discover how a strategic acquisition in pharma packaging is set to drive growth as the market aims to double by 2028
pharmaphorum
DECEMBER 3, 2024
Cytokinetics should hear back from the FDA next September about its application for Camzyos rival aficamten in obstructive hypertrophic cardiomyopathy
Outsourcing Pharma
DECEMBER 3, 2024
Novocure's PANOVA-3 trial shows TTFields therapy with chemotherapy improves survival in pancreatic cancer, marking a significant breakthrough in treatment
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
pharmaphorum
DECEMBER 3, 2024
Ipsen has expanded its oncology pipeline by licensing a T cell engager (TCE) therapy from Paris-based startup Biomunex for up to $610m
Pharmaceutical Commerce
DECEMBER 3, 2024
The agreement provides PTC with $1 billion in cash once deal closes, and is centered around PTC518's development, manufacturing and commercialization.
pharmaphorum
DECEMBER 3, 2024
Tune in to the podcast interview with Dr Sharmeen Roy to learn more about precision dosing and how DoseMe is providing effective and safe treatment for all through personalised dosing solutions.
Pharmaceutical Commerce
DECEMBER 3, 2024
The latest news for pharma industry insiders.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
pharmaphorum
DECEMBER 3, 2024
Get to know Jackie Marchington, an expert in IPG Health Medical Communications, through this exclusive interview. Learn about her insights, experiences, and perspectives on the industry.
CTTI (Clinical Trials Transformation Initiative)
DECEMBER 3, 2024
In December 2022, Congress passed the Food and Drug Omnibus Reform Act (FDORA) requiring drug and device manufacturers to develop and submit diversity action plans (DAPs) for Phase III and other pivotal trials outlining how they plan to recruit, enroll, and retain a population that reflects the patient population with the disease or condition in the US that is expected to use the medical product if approved, licensed, authorized, cleared, or classified.
Sciensano
DECEMBER 3, 2024
Ten years ago, children were more active than they are now. That is according to the Food Consumption Survey by Sciensano, which assessed and measured the physical activity and sedentary behaviour of the Belgian population in 2022-2023. Only 31% of children aged 3 to 9 and 19% of adolescents aged 10 to 17 engage in sufficient physical activity. However, 46% of children and 41% of adolescents walk, bike or use a non-electrical scooter to get to school.
pharmaphorum
DECEMBER 3, 2024
Integrating Expertise from Software Development, Quality Assurance, Regulatory Affairs, & Product Teams to Drive Innovation in Alignment with Global Regulatory Guidelines, AI & ML Enabled Software, Cybersecurity, & Agile Methodologies
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Expert insights. Personalized for you.
246 
Let's personalize your content